Evidence-based research profiles for anabolic-androgenic steroids, selective estrogen receptor modulators, aromatase inhibitors, and post-cycle therapy compounds. Bloodwork monitoring context included. For research use only.
Monitor liver enzymes (AST/ALT), lipids (LDL/HDL), hormones (testosterone, LH, FSH, estradiol), and hematocrit. Our Bloodwork Interpreter covers 27 markers with AAS-specific context for each.
Check AAS + SERM + peptide stacks for conflicts. 25+ named rules, 6 risk dimensions. No login.
Long-acting testosterone ester (7-day half-life) studied as the reference standard for androgen research. Mechanism: androgen receptor agonism. Aromatizes to estradiol via CYP19A1. Most widely used base compound in AAS research.
Read research profile โ Injectable AASEquivalent to enanthate (8โ12 day half-life) with identical mechanism. Studied for TRT protocols and HPA axis regulation. Commonly used as interchangeable research alternative to enanthate due to comparable pharmacokinetics.
Read research profile โ Injectable AAS19-nortestosterone derivative (Deca-Durabolin) with reduced androgenic activity. Studied for anabolic effects, joint lubrication research, and progestin receptor activity. Half-life: 6โ12 days. Low aromatization.
Read research profile โ Injectable AASTestosterone-derived compound (Equipoise) studied for sustained anabolic activity and erythropoiesis stimulation via EPO upregulation. Half-life: 14 days. ~50% aromatization rate vs testosterone.
Read research profile โ Injectable AAS19-nortestosterone derivative with ~5ร androgen receptor affinity of testosterone. Does not aromatize. Strong progestin activity. Studied for nitrogen retention and IGF-1 upregulation mechanisms. Half-life: 3 days.
Read research profile โDHT-derivative studied for anti-estrogenic activity via aromatase inhibition at androgen receptor level. Does not aromatize. Researched for its SHBG-binding interactions and free androgen index effects.
Research profile coming โDHT-derived oral with low androgenicity and mild hepatotoxicity vs other 17ฮฑ-alkylated compounds. Studied for nitrogen retention, SHBG reduction, and IGF-1 stimulation. Half-life: 9โ10 hours. FDA-approved for muscle wasting research.
Read research profile โ17ฮฑ-alkylated DHT-derived compound studied for SHBG-binding reduction and free testosterone elevation. Known for SHBG displacement effects. Moderate hepatotoxicity. Veterinary and human pharmaceutical history.
Research profile coming โFast-acting 17ฮฑ-alkylated testosterone derivative. Studied for rapid nitrogen retention and protein synthesis effects. Significant aromatization. Half-life: 3โ6 hours. First widely researched oral AAS.
Read research profile โDHT-derived 17ฮฑ-alkylated compound studied for erythropoiesis stimulation and hematocrit effects. One of the most potent oral AAS by nitrogen retention metrics. Significant hepatotoxicity risk in research contexts.
Research profile coming โChlorinated Dianabol derivative with reduced aromatization and androgenicity. Studied for SHBG reduction and protein synthesis with longer half-life (16 hours). East German research compound; detected in doping studies.
Research profile coming โFirst-generation SERM studied for estrogen receptor antagonism in breast tissue and agonism in uterus/bone. Used in PCT research to restore LH/FSH pulsatility. Mechanism: competitive ER binding. FDA-approved oncology drug.
Read research profile โ SERMMixed estrogen receptor agonist/antagonist studied for hypothalamic feedback disruption and gonadotropin release. Two isomers: zuclomiphene (agonist) and enclomiphene (antagonist). PCT and male hypogonadism research applications.
Read research profile โ SERMPure trans-clomiphene isomer without the estrogenic zuclomiphene component. Studied for hypothalamic-pituitary-gonadal axis restoration with cleaner LH/FSH stimulation vs racemic Clomid. Phase 3 clinical research for hypogonadism.
Read research profile โ SERMSecond-generation SERM studied for gynecomastia treatment in research contexts. Superior ER antagonism in breast tissue vs Tamoxifen for some glandular tissue studies. FDA-approved for osteoporosis. No uterine stimulation.
Read research profile โ SERMSecond-generation non-steroidal SERM with mixed agonist/antagonist profile. CYP3A4 metabolism (not CYP2D6-dependent) โ more predictable efficacy. Favorable uterine safety profile vs tamoxifen in extended use. FDA-approved for metastatic breast cancer.
Read research profile โNon-steroidal reversible CYP19A1 (aromatase) inhibitor. Studied for estradiol suppression in androgen research protocols. FDA-approved for breast cancer. Mechanism: competitive aromatase enzyme binding. Half-life: ~46 hours.
Read research profile โ Aromatase InhibitorSteroidal irreversible aromatase inactivator. Studied for permanent aromatase enzyme binding without rebound estradiol elevation. FDA-approved. Mildly androgenic due to androstane scaffold. Half-life: ~24 hours.
Read research profile โ Aromatase InhibitorNon-steroidal aromatase inhibitor with highest potency among triazole AIs. Studied for near-complete estrogen suppression (up to 99%). FDA-approved. Used in gynecomastia and estrogen-related research. Half-life: ~48 hours.
Read research profile โLH analog studied for testicular Leydig cell stimulation and spermatogenesis maintenance. Mimics LH/FSH action on gonadal axis. Used in PCT research to preserve testicular volume and restore testosterone production during/after cycles.
Read research profile โ PCT / SupportBile acid studied for hepatoprotective activity against 17ฮฑ-alkylated AAS hepatotoxicity. Mechanism: mitochondrial membrane stabilization, ER stress reduction. Also studied for cholestasis and neurodegenerative research contexts.
Read research profile โ PCT / SupportGlutathione precursor studied for hepatoprotection via oxidative stress reduction. Standard liver support compound in AAS research contexts. Also researched for respiratory, psychiatric, and acetaminophen toxicity applications.
Read research profile โ PCT / SupportDopamine D2/D3 agonist studied for prolactin suppression in 19-nortestosterone (nandrolone, trenbolone) research protocols. FDA-approved for hyperprolactinemia. Mechanism: inhibits pituitary prolactin secretion. Half-life: 63โ68 hours.
Read research profile โ PCT / SupportOral 1ฮฑ-methyl DHT derivative studied for SHBG displacement and free testosterone elevation in AAS research. Mildly androgenic, non-aromatizable, not hepatotoxic via 17ฮฑ-alkylation. Researched for androgenic support and male fertility. Half-life: ~12 hours.
Read research profile โDual 5ฮฑ-reductase inhibitor (types 1 + 2) studied for DHT reduction in androgen-sensitive tissue research. ~90% DHT suppression vs finasteride's ~70%. Researched for scalp androgen receptor interaction during AAS cycles. Half-life: ~5 weeks.
Research profile coming โThe Bloodwork Interpreter covers liver function (AST, ALT, GGT, bilirubin), lipid panel (LDL, HDL, triglycerides), hormones (Total T, Free T, LH, FSH, estradiol, prolactin, SHBG), kidney markers, CBC, and more โ all with compound-specific context.